Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | CCR6 | P51684 | 1/20 | 0.55 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | WRN | Q14191 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionic Acid SCHEMBL28981241 | 0.98 | GSK3A (0.52) | GSK3AGSK3BCCR6FFAR3ALDH1A1 | |
| Tetraethylene Glycol SCHEMBL29007236 | 0.84 | MEN1 (0.39) | GSK3AGSK3BCCR6FFAR3ALDH1A1 | |
| Butyric Acid SCHEMBL714988 | 0.84 | FFAR3 (0.56) | GSK3AGSK3BCCR6FFAR3ALDH1A1 | |
| SCHEMBL22981743 | 0.83 | GSK3A (0.52) | GSK3AGSK3BCCR6ALDH1A1CYP1A2 | |
| Propionamide SCHEMBL21359983 | 0.83 | GSK3A (0.52) | GSK3AGSK3BCCR6ALDH1A1CYP1A2 | |
| Glycolic Acid SCHEMBL29471409 | 0.82 | GSK3A (0.58) | GSK3AGSK3BCCR6HTTCA12 | |
| Succinic Acid SCHEMBL4127642 | 0.82 | GSK3A (0.58) | GSK3AGSK3BCCR6ALDH1A1CYP2C19 | |
| Acetic Acid SCHEMBL29870582 | 0.81 | GSK3A (0.65) | GSK3AGSK3BCCR6FFAR3 | |
| Acetic Acid SCHEMBL208214 | 0.81 | GSK3A (0.65) | GSK3AGSK3BCCR6FFAR3 | |
| Propionic Acid SCHEMBL28981239 | 0.81 | GSK3A (0.50) | GSK3AGSK3BCCR6FFAR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250135043-A1 | DUAL-TARGETING COMPOUND FOR FIBROBLAST ACTIVATION PROTEIN (FAP) AND INTEGRIN avB3, PREPARATION METHOD THEREFOR AND USE THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO., LTD. (CN) | 2025-05-01 | — | — | US | claimed |
| CN-119736236-A | Hydrogel for 3D culture of stem cells/organoids and preparation method thereof | 昆明理工大学 | 2025-04-01 | — | — | CN | claimed |
| CN-119529003-A | Albumin-binding doxorubicin prodrug, self-assembled nanoparticle thereof and application thereof | 沈阳药科大学 | 2025-02-28 | — | — | CN | claimed |
| CN-118290405-B | Fluorescent probe for targeting SLC7A5 high-expression tumor and preparation method and application thereof | 江苏省人民医院（南京医科大学第一附属医院） | 2025-02-28 | — | — | CN | claimed |
| CN-118290405-A | Fluorescent probe for targeting SLC7A5 high-expression tumor and preparation method and application thereof | 江苏省人民医院（南京医科大学第一附属医院） | 2024-07-05 | — | — | CN | claimed |
| CN-116392642-A | Extracellular matrix/glycopeptide hydrogel for heart failure treatment and preparation method thereof | 中国医学科学院生物医学工程研究所 | 2023-07-07 | — | — | CN | claimed |
| CN-115895176-A | Rubber processing aid and preparation method thereof | 常州市五洲环保科技有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-115300640-A | Novel linkers and their use for specific coupling of drugs and biomolecules | 杭州多禧生物科技有限公司 | 2022-11-08 | — | — | CN | claimed |
| CN-113698335-A | Specific conjugation of cell binding molecules | 杭州多禧生物科技有限公司 | 2021-11-26 | — | — | CN | claimed |
| CN-111214461-B | Preparation and application of sugar-targeted modified siRNA (small interfering ribonucleic acid) nanoparticles | 河南大学 | 2021-04-16 | — | — | CN | claimed |
| CN-103732238-A | Therapeutic compounds for immunomodulation | AURIGENE DISCOVERY TECH LTD | 2014-04-16 | — | — | CN | claimed |
| CN-1956998-B | Method for the purification of albumin conjugates | CONJUCHEM INC | 2012-12-12 | — | — | CN | claimed |
| CN-101918841-A | Peptide-lipid constructs and their use in diagnostic and therapeutic applications | CRISTINA-SIMONA WEINBERG | 2010-12-15 | — | — | CN | claimed |
| CN-101696240-A | Long lasting growth hormone releasing factor derivatives | CONJUCHEM INC | 2010-04-21 | — | — | CN | claimed |
| EP-2016942-A1 | Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders | CELGENE CORPORATION (US) | 2009-01-21 | — | — | EP | claimed |
| US-20080146783-A1 | Method for the purification of albumin conjugates | CONJUCHEM BIOTECHNOLOGIES INC. | 2008-06-19 | — | — | US | claimed |
| CN-1956998-A | Method for the purification of albumin conjugates | CONJUCHEM INC (CA) | 2007-05-02 | — | — | CN | claimed |
| EP-1242082-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORPORATION (US) | 2002-09-25 | — | — | EP | claimed |
| US-20020054899-A1 | Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders | CELGENE CORP. | 2002-05-09 | — | — | US | claimed |
| WO-2001043743-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORP. (US) | 2001-06-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250135043-A1 | DUAL-TARGETING COMPOUND FOR FIBROBLAST ACTIVATION PROTEIN (FAP) AND INTEGRIN avB3, PREPARATION METHOD THEREFOR AND USE THEREOF | FAP, ITGAV, ITGB3 | GSK3A 1063/4885GSK3B 645/4885CCR6 2332/4885 |
| US-20080146783-A1 | Method for the purification of albumin conjugates | ALB, DNPEP, SLC7A1 | GSK3A 4403/4885GSK3B 4684/4885CCR6 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.